Recombinant factor VIa (rF.VIIa) is a twochain procoagulant enzyme (Mr, =50,000) active only when complexed with tissue factor in the extrinsic clotting system. We administered human rF.VIIa to hemophilic and von Willebrand disease (vWD) dogs to determine its hemostatic effectiveness and survival in the circulation. Hemophilia A dogs lacking factor VIII demonstrated an immediate increase in plasma rF.VIIa and prompt stoppage of hemorrhage at bleeding time (BT) sites. In seven studies in two dogs, the range of dose of rF.VIIa was 50-220 ,ug/kg, with an apparent 7-to 11-fold increase in plasma factor VII and a mean recovery in plasma of 34%. The til2 was 2.8 ± 0.5 hr. The BT was normalized except in an animal given the minimum dose. In four studies in two hemophilia B dogs lacking factor IX, BT was normalized. The elevation in plasma factor VII was by a factor of 8-30, with a mean recovery of rF.VIIa in plasma of 44%. In two studies in a homozygous vWD dog lacking von Willebrand factor, which is needed for platelet function, BT was not corrected even though large doses of rF.VIIa were given. The human rF.VIIa protein was immunogenic for dogs. These studies indicate that factor VIa corrects the hemostatic defect in dogs with hemophilia A and B, diseases primarily of the intrinsic clotting system, but does not correct the hemostatic defect in vWD.
The pathophysiology of hemophilia A and hemophilia B is determined by the lack of specific plasma procoagulant proteins, factors VIII and IX, respectively. In each disease, there is impairment of the intrinsic pathway of coagulation, with inadequate thrombin generation and defective hemostasis. Infusions of the missing protein correct the hemostatic defect except when an alloantibody has developed that neutralizes the antihemophilic factor (inhibitor hemophilia). It has long been recognized that the extrinsic pathway of coagulation involving tissue factor (TF) and factor VII may also be impaired in hemophilia A (1) . It was demonstrated 50 years ago that the very slow thrombin generation in hemophilic blood can be corrected by addition of small amounts of TF-i.e., thromboplastin (2), the TF effect being dose dependent. If only a trace of TF is used, the clotting of both human and canine hemophilic plasma remains long (3) . This is the basis of the dilute thromboplastin time test for hemophilia, in which factor VII appears to be incompletely activated to form factor VIa (4) . The prolonged dilute thromboplastin time in hemophilia, while not completely understood, may be due to impaired factor VII activation in this disease (5) , possibly the result of lack of factor VIII or IX (6) . Normally factor VIIa, complexed with TF, forms the active enzyme that converts factor X to Xa, which in turn converts prothrombin to thrombin in the presence of factor Va. The complex also converts factor IX to factor IXa (7), thus representing a link between the intrinsic and extrinsic pathways. The mechanism of action of TF and factor VII has been reviewed (8, 9) .
Additional evidence for a possible role of the extrinsic system in hemophilia came from infusing plasma concentrates containing the activated procoagulant enzymes, factors IXa, Xa, and VIla, to "bypass" the defect in inhibitor hemophilia. Such concentrates had a hemostatic effect, but thrombosis was observed with higher dosage (10, 11) . The purification of factor VII from plasma (12) allowed preliminary testing of isolated human factor VIa in microgram amounts in inhibitor hemophilia. The results pointed to this procoagulant as an active bypassing agent (13) . Recently, human factor VII has been cloned and expressed in mammalian cells (14) , making it possible to produce this trace protein in larger amounts than heretofore. During purification, recombinant factor VIIa (25) . Factor VII-deficient plasma for substrate was prepared from normal human plasma by immunoadsorption using a mAb raised against plasma-derived factor VII. Factor VII antigen in plasma was determined by a double monoclonal ELISA, using two mAbs directed against different epitopes on the factor VII molecule. One mAb, the catching antibody, was bound to the microtiter plate and the test plasma was added. After addition of the second mAb, an immunoperoxidase-labeled anti-mouse IgG was used. The mAb did not cross-react with canine factor VII. Human plasma was used as a standard.
Other Coagulation Assays. Factor VIII:C assays were performed by a modified one-stage method (3) using a kaolin-activated procedure with canine hemophilia A plasma as substrate. Factor IX assays were done with the same procedure, using canine hemophilia B plasma as substrate. Partial thromboplastin time (PTT) determinations were performed essentially as described (3). The activated partial thromboplastin time (APTT) determinations were performed by using an APTT reagent (Pacific Hemostasis, Ventura, CA), following the manufacturer's directions. Dilute thromboplastin time tests (3) were performed with a rabbit brain thromboplastin reagent (Sigma Diagnostics) diluted to 1: 25,000 in 0.154 M NaCl. The procedure was a three-part test consisting of 1 part each of undiluted citrated plasma and dilute thromboplastin incubated 3 min at 37°C. The clotting time was determined after the addition of 1 part 0.025 M CaCl2. von Willebrand factor (vWF) assays were done with botrocetin using the macroscopic tap-tube procedure with Iyophilized human platelets (26, 27) . A group of assays was performed to monitor for evidence of disseminated intravascular coagulation following infusions of rF.VIIa. Fibrinogen levels were determined by a syneresis method (28 kg of body weight. The expected and actual plasma levels of factor VIla antigen immediately postinfusion indicate a mean retention in the circulation of 34% ± 13% of the injected dose, with a range of 18% to 48%. The plasma levels of factor VII were elevated from 4-to 11-fold above preinjection values. The fall-offs of plasma factors VII and VII antigen are illustrated in Fig. 1A . At 24 hr, the levels of these factors had returned to preinfusion values. The ti12 for factor VII was 2.1 + 0.6 hr and for factor VII antigen it was 2.8 ± 0.5 hr. The postinfusion BT was B infusion of a sufficient amount of rF.VIIa without induction of a systemic clotting reaction. Four infusions of rF.VIIa were given to two hemophilia B animals ( Table 1 , Exps. 8-11). The range of dose of rF.VIIa was 67-199 pg/kg. The postinfusion plasma levels of factor VII were increased 8.3-30.7 units/ml. The mean postinfusion recovery of rF.VIIa antigen in the plasma was 44% ± 6%. These values were higher than in the hemophilia A dogs with comparable doses of rF.VIIa. The correction of the hemostatic defect was similar to that observed in the hemophilia A dogs. Fig. 1B provides data illustrating the loss over time of the effect of rF.VIIa infusions. The basal values for the PTT and the APTT tests were longer in the hemophilia B dogs than in those with hemophilia A, and both tests were shortened after rF.VIIa infusions. The tests for systemic clotting were negative. Plasma factor IX was undetectable throughout the experiments. These data indicate that the hemophilia B dogs, like the hemophilia A animals, respond to rF.VIIa infusions by correction of the hemostatic defect and without evidence of systemic coagulation.
Effect of rF.VIIa on in Vitro Clotting of Hemophilic Plasmas. In view of the shortening of both the PTT and the dilute thromboplastin time in hemophilia A and hemophilia B dogs given rF.VIIa, the effect of adding rF.VIIa in vitro on the prolonged clotting time of the hemophilic plasmas in these tests was determined. Fig. 2 illustrates the progressive shortening of hemophilia A and hemophilia B plasmas with increasing concentrations of rF.VIIa. The highest concentration of rF.VIIa corresponds to -70 units of factor VII per ml. Higher concentrations of rF.VIIa up to 500 units/ml reduced the PTT to a minimum of =20 sec for both plasmas. Illustrations of infusions in a hemophilia A dog ( ,.g/kg).
shortened to the normal range of <5 min except in Exp. 1, in which a low dose of rF.VIIa was administered. At 6 hr postinfusion (Fig. 1A) , the BT had returned to basal levels, although in a few experiments a shortened BT was still noted. Both the activated and unactivated PTTs were determined at intervals before and after rF.VIIa infusions. The APTT values were affected very little by the infusions. In contrast, the PTT values were considerably shortened (Table 1) . Some shortening of the PTT persisted at 6 hr but not at 24 hr (Fig.  1A) . The Response of a vWD Dog to Infused rF.VIIa. Two infusions were given to a vWD animal. The doses of rF.VIIa were considerably larger than those given to the hemophilic animals, and the increase in plasma levels of factor VII and factor VII antigen was correspondingly greater (Table 1 , Exps. 12 and 13). The mean recovery of factor VII antigen immediately postinfusion was 40%. There was no corrective effect on the long BT.
Immunologic Response of Bleeder Animals to Human rF.Vlla. A transient urticarial-type reaction lasting for -30 min occurred on only one occasion in four of the five bleeder animals within 10 min following the injection of rF.VIIa (Table 1 , Exps. 7, 10-12). Wheals appeared most prominently about the face. Anti-human factor VII antibodies were detected in the plasmas of all animals 1-2 wk after the animals received the first dose of rF.VIIa. The response of the animals varied and appeared unrelated to the dose of rF.VIIa. Dog 2 was a low responder, with antibody being detected in the 2-wk sample only (titer, 1:100). The remaining dogs had a maximum titer of 1:1000. The antibody persisted for 10 wk in dogs 3 and 4, and for 22 and 29 wk in dogs 5 and 1, respectively.
DISCUSSION
The availability of rF.VIIa permitted the testing of its hemostatic properties over a wide range of dosages in the two hemophilic diseases, canine hemophilia A and B. The recipient's plasma levels of factor VII were elevated many times the physiological amounts. The secondary toenail BT test was used as the hemostatic test, since the primary toenail BT is normal in hemophilic dogs (3-5 min). The secondary BT was performed by shaving off the clot at the primary site to restart bleeding. In hemophilic subjects, the secondary BT is >15 min; in normal animals, it is <5 min (22) . The design of the experiments was to test the effect of rF.VIIa in two ways: (i) infusion before the secondary BT was done-i.e., prevention of prolonged bleeding and (ii) infusion while the nail was actively bleeding-i.e., stanching of bleeding in progress. With each schedule the defective hemostasis in both types of hemophilia was immediately corrected by infusions of similar doses of rF.VIIa. These events suggest that activation of factor IX by the rF.VIIa-TF complex is not essential for its hemostatic effect in hemophilia. The two hemophilic diseases are due to a deficiency of different proteins that act in a different manner in the intrinsic coagulation pathway. The tl2 of injected rF.VIIa in these experiments was in the 2-to 3-hr range, similar to that observed in inhibitor hemophilia A patients given clinical factor IX concentrates (32) . The administration of rF.VIIa in excess seems to induce normal hemostasis in the hemophilic dogs, bypassing the activation of factor IXa and perhaps activation of factor VII as well.
Determination of plasma factor VII levels after rF.VIIa infusions can be made with either the factor VII bioassay or immunoassay procedures. Both the PTT and the dilute thromboplastin time tests appear to be suitable for monitoring changes in plasma rF.VIIa levels. The clotting times in these tests are prolonged in hemophilia A and B and are shortened by infusions of rF.VIla in the hemophilic dogs (Fig. 1) or by addition of rF.VIIa in vitro to their plasmas (Figs. 2 and 3 
